Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
C HesdorfferK Antman

Abstract

Normal bone marrow cells have little or no expression of the MDR p-glycoprotein product and, therefore, are particularly susceptible to killing by MDR-sensitive drugs, such as vinca alkaloids, anthracyclines, podophyllins, and paclitaxel and its congeners. Here we report the results of a phase I clinical trial that tested the safety and efficacy of transfer of the human multiple drug resistance (MDR1, MDR) gene into hematopoietic stem cells and progenitors in bone marrow as a means of providing resistance of these cells to the toxic effects of cancer chemotherapy. Up to one third of the harvested cells of patients who were undergoing autologous bone marrow transplantation as part of a high-dose chemotherapy treatment for advanced cancer were transduced with an MDR cDNA-containing retrovirus; these transduced cells were reinfused together with unmanipulated cells after chemotherapy. High-level MDR transduction of erythroid burst-forming unit (BFU-E) and colony-forming unit-granulocyte macrophage (CFU-GM) derived from transduced CD34+ cells was shown posttransduction and prereinfusion. However, only two of the five patients showed evidence of MDR transduction of their marrow at a low level at 10 weeks and 3 weeks, respectively, p...Continue Reading

Citations

Oct 31, 2000·Current Opinion in Hematology·M SadelainI Rivière
May 25, 2001·International Journal of Hematology·J Richter, S Karlsson
Jun 6, 2002·Journal of Cellular Biochemistry. Supplement·Malcolm A S Moore
Sep 18, 2002·Proceedings of the National Academy of Sciences of the United States of America·W PfutznerJ C Vogel
Dec 30, 2003·Journal of Surgical Oncology·Rhiannon M Hughes
Oct 8, 2005·Cancer Gene Therapy·M ZaboikinF Schuening
Sep 21, 2007·The Journal of Gene Medicine·Ellen A M Schenk-BraatLeonie C M Kaptein
Dec 15, 2015·Journal of Experimental & Clinical Cancer Research : CR·Sebastian BrennigThomas Moritz
Feb 27, 1999·Current Opinion in Obstetrics & Gynecology·S L McAfee, M V Seiden
Sep 13, 2000·Drugs & Aging·P W Szlosarek, A G Dalgleish
Apr 12, 2001·Journal of Internal Medicine·M K Brenner
Aug 22, 2002·Nature Reviews. Cancer·Brian P Sorrentino
Jan 4, 2007·American Journal of Veterinary Research·Shinobu MatsuuraHajime Tsujimoto
Jul 23, 2005·Cancer Gene Therapy·Tulin Budak-AlpdoganJoseph R Bertino
Feb 28, 2015·Cancer Gene Therapy·W H Everett, D T Curiel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2021 Meta ULC. All rights reserved